PK of BI 1356 in Healthy Chinese Volunteers

Phase 1, open-label, single-arm trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration of the analyte in plasma at steady state and Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval tau. Started Jul 2009; status: completed.